Active Surveillance Economical Over Immediate Treatment for Low-Risk Prostate Cancer

Researchers in Canada have developed a model to simulate the cost of active surveillance versus immediate treatment among low-risk prostate cancer patients.
Published Online: May 08, 2014

Active surveillance for low-risk prostate cancer in Canada could save nearly $100 million annually without worsening quality-adjusted life expectancy (QALE), according to results of a simulation comparing active surveillance with immediate treatment.

Many prostate cancers, especially those in the low-risk category, are indolent and may not require immediate treatment. At least one study has showed that QALE is greater for active surveillance than for brachytherapy, intensity-modulated radiotherapy, or radical prostatectomy.

Still, despite published guideline recommendations, as many as 90% of men with prostate cancer receive immediate treatment. Such overtreatment can be a tremendous financial burden to healthcare systems.

To see how costly it might be, Dr. Alice Dragomir and colleagues from McGill University in Montreal developed a Markov model with Monte Carlo microsimulations to estimate the direct cost associated with active surveillance and immediate treatment for low-risk prostate in Canada.

Then, they compared Canadian and US cost estimates, and published their findings online April 24th in CMAJ Open.

Source: Medscape



Feature
Recommended Articles
A research team at the Barts Cancer Institute in London has identified a 3-protein molecular signature in pancreatic cancer patients.
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
The discovery could lead to targeted therapy in triple negative breast cancer patients.
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.